Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?

Giuseppe Vizzielli, Francesco Fanfani, Vito Chiantera, Lucia Tortorella, Alessandro Lucidi, Marco Petrillo, Barbara Costantini, Giovanni Scambia, Anna Fagotti

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: To compare prognosis of advanced epithelial ovarian cancer (AEOC) patients based on where the first surgical assessment was performed. Patients and Methods: Retrospective analysis of primary AEOC patients was performed and three groups were formed based on where the decision of primary treatment was taken: Internal, if the decision was carried out at our Institution (PDS (Primary Debulking Surgery), I-IDS (Internal-Interval Debulking Surgery)) and Referred in case women were referred after neoadjuvant chemotherapy (NACT) from other Centers (R-IDS (Referred- Interval Debulking Surgery)). Results: Among 573 AEOC, 279 (48.7%) were PDS and 294 (51.3%) IDS. In particular, 134 of 294 (45.6%) were R-IDS and 160 (54.4%) were I-IDS. Median progression-free survival (PFS) was 26 months in PDS, 14 months in I-IDS and 17 months in R-IDS. The difference was statistically significant (p

Original languageEnglish
Pages (from-to)3027-3032
Number of pages6
JournalAnticancer Research
Volume35
Issue number5
Publication statusPublished - May 1 2015

Fingerprint

Ovarian Neoplasms
Drug Therapy
Disease-Free Survival
Ovarian epithelial cancer
Therapeutics

Keywords

  • Cytoreduction
  • Interval debulking surgery
  • Ovarian cancer
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Vizzielli, G., Fanfani, F., Chiantera, V., Tortorella, L., Lucidi, A., Petrillo, M., ... Fagotti, A. (2015). Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy? Anticancer Research, 35(5), 3027-3032.

Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy? / Vizzielli, Giuseppe; Fanfani, Francesco; Chiantera, Vito; Tortorella, Lucia; Lucidi, Alessandro; Petrillo, Marco; Costantini, Barbara; Scambia, Giovanni; Fagotti, Anna.

In: Anticancer Research, Vol. 35, No. 5, 01.05.2015, p. 3027-3032.

Research output: Contribution to journalArticle

Vizzielli, G, Fanfani, F, Chiantera, V, Tortorella, L, Lucidi, A, Petrillo, M, Costantini, B, Scambia, G & Fagotti, A 2015, 'Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?', Anticancer Research, vol. 35, no. 5, pp. 3027-3032.
Vizzielli G, Fanfani F, Chiantera V, Tortorella L, Lucidi A, Petrillo M et al. Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy? Anticancer Research. 2015 May 1;35(5):3027-3032.
Vizzielli, Giuseppe ; Fanfani, Francesco ; Chiantera, Vito ; Tortorella, Lucia ; Lucidi, Alessandro ; Petrillo, Marco ; Costantini, Barbara ; Scambia, Giovanni ; Fagotti, Anna. / Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?. In: Anticancer Research. 2015 ; Vol. 35, No. 5. pp. 3027-3032.
@article{7ab08e50e38a4783a841d1081c9e95f6,
title = "Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?",
abstract = "Aim: To compare prognosis of advanced epithelial ovarian cancer (AEOC) patients based on where the first surgical assessment was performed. Patients and Methods: Retrospective analysis of primary AEOC patients was performed and three groups were formed based on where the decision of primary treatment was taken: Internal, if the decision was carried out at our Institution (PDS (Primary Debulking Surgery), I-IDS (Internal-Interval Debulking Surgery)) and Referred in case women were referred after neoadjuvant chemotherapy (NACT) from other Centers (R-IDS (Referred- Interval Debulking Surgery)). Results: Among 573 AEOC, 279 (48.7{\%}) were PDS and 294 (51.3{\%}) IDS. In particular, 134 of 294 (45.6{\%}) were R-IDS and 160 (54.4{\%}) were I-IDS. Median progression-free survival (PFS) was 26 months in PDS, 14 months in I-IDS and 17 months in R-IDS. The difference was statistically significant (p",
keywords = "Cytoreduction, Interval debulking surgery, Ovarian cancer, Prognosis",
author = "Giuseppe Vizzielli and Francesco Fanfani and Vito Chiantera and Lucia Tortorella and Alessandro Lucidi and Marco Petrillo and Barbara Costantini and Giovanni Scambia and Anna Fagotti",
year = "2015",
month = "5",
day = "1",
language = "English",
volume = "35",
pages = "3027--3032",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?

AU - Vizzielli, Giuseppe

AU - Fanfani, Francesco

AU - Chiantera, Vito

AU - Tortorella, Lucia

AU - Lucidi, Alessandro

AU - Petrillo, Marco

AU - Costantini, Barbara

AU - Scambia, Giovanni

AU - Fagotti, Anna

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Aim: To compare prognosis of advanced epithelial ovarian cancer (AEOC) patients based on where the first surgical assessment was performed. Patients and Methods: Retrospective analysis of primary AEOC patients was performed and three groups were formed based on where the decision of primary treatment was taken: Internal, if the decision was carried out at our Institution (PDS (Primary Debulking Surgery), I-IDS (Internal-Interval Debulking Surgery)) and Referred in case women were referred after neoadjuvant chemotherapy (NACT) from other Centers (R-IDS (Referred- Interval Debulking Surgery)). Results: Among 573 AEOC, 279 (48.7%) were PDS and 294 (51.3%) IDS. In particular, 134 of 294 (45.6%) were R-IDS and 160 (54.4%) were I-IDS. Median progression-free survival (PFS) was 26 months in PDS, 14 months in I-IDS and 17 months in R-IDS. The difference was statistically significant (p

AB - Aim: To compare prognosis of advanced epithelial ovarian cancer (AEOC) patients based on where the first surgical assessment was performed. Patients and Methods: Retrospective analysis of primary AEOC patients was performed and three groups were formed based on where the decision of primary treatment was taken: Internal, if the decision was carried out at our Institution (PDS (Primary Debulking Surgery), I-IDS (Internal-Interval Debulking Surgery)) and Referred in case women were referred after neoadjuvant chemotherapy (NACT) from other Centers (R-IDS (Referred- Interval Debulking Surgery)). Results: Among 573 AEOC, 279 (48.7%) were PDS and 294 (51.3%) IDS. In particular, 134 of 294 (45.6%) were R-IDS and 160 (54.4%) were I-IDS. Median progression-free survival (PFS) was 26 months in PDS, 14 months in I-IDS and 17 months in R-IDS. The difference was statistically significant (p

KW - Cytoreduction

KW - Interval debulking surgery

KW - Ovarian cancer

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84929692961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929692961&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 3027

EP - 3032

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -